Navigation Links
ESBATech's Lead Antibody Fragment Enters Clinical Development for Ophthalmic Indications
Date:4/24/2008

ogy platform for therapeutic antibody fragments, we started preclinical development of ESBA105 in mid 2006. Now to move this swiftly into the clinic is a truly exciting time for the company. ESBA105 represents a new generation of antibody fragment therapeutics that have favourable biochemical properties over earlier classes of antibody fragments, such as high stability, solubility and high monomeric content. This allows us to deliver the drug topically, without any need to stabilize or modify the protein. Thanks to the small protein size as compared to conventional antibodies, ESBA105 efficiently penetrates into all segments of the eye, which results in a high local concentration where the drug is needed to inhibit inflammation. As this is associated with low systemic drug exposure, this novel therapeutic approach has a very low risk of provoking systemic adverse effects."

ESBATech is the first and only company to date that has successfully screened and characterized the entire human pool (1.5 million) of naturally occurring variable immunoglobulin (VH and VL) domains to select highly stable, soluble and monomeric single-chain antibody fragments frameworks. The company is advancing a pipeline of novel, antibody fragment therapeutics for topical and/or local delivery, to ensure safe and convenient patient therapy.

About ESBATech AG

ESBATech AG is a Zurich, Switzerland-based, privately held drug discovery and development company focused on advancing antibody fragments for therapeutic applications. The company applies its proprietary, fully human single-chain antibody frameworks to generate product candidates against targets of clinical relevance. ESBATech is focused on delivering high concentrations of its therapeutic antibody fragments to the targeted sites, in combination with extremely low systemic load, in order to achieve low risk of systemic drug reactions using topical and local delivery. Current venture investors include SV Life Sciences,
'/>"/>

SOURCE ESBATech AG
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors
2. MedImmune Advances Asthma Program with Start of a Phase 2 Trial in Europe and Australia and First U.S.-Based Clinical Trial for Antibody Targeting IL-13
3. OncoMed Chooses SynCo Bio Partners to Fill and Finish its Lead Antibody
4. Micromet Shows Feasibility of Subcutaneous Delivery of BiTE Antibody in Preclinical Primate Study
5. Genaera Announces MedImmune Initiation of Phase 2a Trial of Antibody Targeting Interleukin-9 in Patients with Asthma
6. MedImmune Advances Clinical Development of Antibody Targeting Interleukin-9 in Patients with Asthma
7. Micromet Announces Presentation of Five Posters Related to Its Proprietary BiTE Antibody Platform at Annual Meeting of American Association for Cancer Research
8. Raven Announces Completion of Enrollment in the Phase 1/2a Clinical Trial of RAV12 Therapeutic Antibody for the Treatment of Adenocarcinomas
9. Micromet Announces the Publication of BiTE Antibody Review in Drugs of the Future
10. Celltrion and CSL Announce Collaboration to Develop and Manufacture Monoclonal Antibody
11. Preclinical Studies Show Promise for Novel Antibody Therapy to Treat Acute Myeloid Leukemia (AML)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... Aug. 31, 2015  Diplomat Pharmacy, Inc. (NYSE: DPLO ... Phil Hagerman , Chairman & CEO, and Sean ... Mr. Hagerman and Mr. Whelan are scheduled ... Boston on Wednesday, September 9, 2015 ... Whelan are also scheduled to participate in the Robert W. ...
(Date:8/31/2015)... AVIV, Israel , August 31, 2015 /PRNewswire/ ... Ltd. (TASE: BOLT, OTCQX: BLGTY) ("BioLight" or ... and commercializes biomedical innovations in ophthalmology and cancer ... Micromedic Technologies (TASE: MCTC), has identified several new ... of the jawbone in patients treated with bisphosphonate ...
(Date:8/31/2015)... 31, 2015  Soligenix, Inc. (OTCQB: SNGX) ... developing products that address unmet medical needs in ... today it has completed enrollment of the additional ... (DRC) earlier this year, into the company,s Phase ... innate defense regulator (IDR) and is being evaluated ...
Breaking Medicine Technology:Diplomat to Participate in Upcoming Investor Conferences 2BioLight Reports Positive Clinical Study Results for Identifying New Genetic Markers to Predict Risk of Developing BRONJ 2BioLight Reports Positive Clinical Study Results for Identifying New Genetic Markers to Predict Risk of Developing BRONJ 3BioLight Reports Positive Clinical Study Results for Identifying New Genetic Markers to Predict Risk of Developing BRONJ 4Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 2Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 3Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 4Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 5Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 6
... Aug. 31 /PRNewswire/ Reportlinker.com announces that a new ... Insulin Pumps - Global Pipeline ... http://www.reportlinker.com/p0254536/Insulin-Pumps---Global-Pipeline-Analysis-Opportunity-Assessment-and-Market-Forecasts-to-2016.html ... and Market Forecasts to 2016 ...
... (NYSE: HRC ) today announced the appointment ... Chain.  Currently serving as General Manager for Global Lean ... on September 13, 2010.  In addition to his responsibilities ... will be responsible for all aspects of Hill-Rom,s global ...
Cached Medicine Technology:Reportlinker Adds Insulin Pumps - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 2Reportlinker Adds Insulin Pumps - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 3Reportlinker Adds Insulin Pumps - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 4Reportlinker Adds Insulin Pumps - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 5Reportlinker Adds Insulin Pumps - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 6Reportlinker Adds Insulin Pumps - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 7Reportlinker Adds Insulin Pumps - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 8Reportlinker Adds Insulin Pumps - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 9Hill-Rom Appoints Scott Jeffers as Senior Vice President, Global Supply Chain 2
(Date:8/31/2015)... ... August 31, 2015 , ... Physicians’ ... Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® meeting, is seeking ... 6 in New York City. The annual legacy meeting uses a variety of ...
(Date:8/31/2015)... New York, New York (PRWEB) , ... August 31, 2015 , ... ... eyes to autumn, when play-offs and the World Series will dominate the sports world. ... its division and eventually advance to the final series. For children, especially those who ...
(Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... ... with e-Spirit to future-proof its content management system (CMS) and make website updates ... Digital Sports in making the websites of the Bundesliga (the German equivalent of ...
(Date:8/31/2015)... , ... August 31, 2015 , ... For 12 years, ... have acknowledged September 26th as Mesothelioma Awareness Day . On this day, and ... with several ways of becoming involved and helping the cause. , “One of the ...
(Date:8/31/2015)... ... August 31, 2015 , ... Chicago-based company The Mood ... to raise money and awareness for breast and ovarian health. During September ... incandescent Mood-lite sold to Bright Pink® to encourage households, dorms, and offices around ...
Breaking Medicine News(10 mins):Health News:Physicians’ Education Resource® Seeks Abstracts for the Upcoming Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® 2Health News:Physicians’ Education Resource® Seeks Abstracts for the Upcoming Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® 3Health News:Physicians’ Education Resource® Seeks Abstracts for the Upcoming Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® 4Health News:New Children's Baseball Series Offers Young Fans a Way to Celebrate the World Series 2Health News:On the Ball with FirstSpirit: German Soccer League (DFL Digital Sports) Opts for e-Spirit’s CMS 2Health News:Cancer Research Organization Paints the World in Mesothelioma Awareness 2Health News:Cancer Research Organization Paints the World in Mesothelioma Awareness 3Health News:Mood-lites® is proud to launch “Brighten Our World" Campaign to Raise Money and Awareness for Breast and Ovarian Health Across America in Partnership with Bright Pink® 2Health News:Mood-lites® is proud to launch “Brighten Our World" Campaign to Raise Money and Awareness for Breast and Ovarian Health Across America in Partnership with Bright Pink® 3
... are the oldest delivery method available, they are ... Several factors have contributed to this trend, the ... of insulin pens. (Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO )New analysis ... , European Insulin Delivery Devices Market , ...
... Florida orthopedic surgeon Dr. Steve Meadows is one of the few ... ... Delray Beach, FL (PRWEB) March 17, 2009 -- A breakthrough shoulder ... lost the mobility in their arm from a damaged rotator cuff, ...
... ... Newark, DE (PRWEB) March 17, 2009 ... ) have demonstrated that single embryos cultured under proper conditions ... successfully in women under age 35. In national results ...
... President of,Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) ... on Wednesday, March 18th at 10:10 AM,in the Harbor ... Philips was named President of ... was Vice President and General Manager of Bayer Healthcare ...
... costs that businesses pay to care for one premature baby ... dozen healthy, full-term infants, according to new statistics from the ... healthy full-term babies from birth through their first birthday was ... paid for by health plans, according to the new data. ...
... Inc. , the Northeast Ohio venture development organization that ... Case Technology Ventures (CTV) , a pre-seed stage ... Western Reserve University , recently announced an investment commitment ... Cleveland, OH company commercializing neurostimulation technology developed at ...
Cached Medicine News:Health News:Insulin Pens and Growing Diabetic Community Increase Market for Insulin Delivery Devices in Europe, Says Frost & Sullivan 2Health News:Insulin Pens and Growing Diabetic Community Increase Market for Insulin Delivery Devices in Europe, Says Frost & Sullivan 3Health News:Insulin Pens and Growing Diabetic Community Increase Market for Insulin Delivery Devices in Europe, Says Frost & Sullivan 4Health News:Innovative Shoulder Surgery Offers Exciting New Option for South Florida Residents with Severe Shoulder Problems 2Health News:Innovative Shoulder Surgery Offers Exciting New Option for South Florida Residents with Severe Shoulder Problems 3Health News:Innovative Shoulder Surgery Offers Exciting New Option for South Florida Residents with Severe Shoulder Problems 4Health News:Most IVF Patients Under 35 Should Have Single Embryo Transfer, According to Latest SART Data 2Health News:Most IVF Patients Under 35 Should Have Single Embryo Transfer, According to Latest SART Data 3Health News:Cell Therapeutics, Inc. (CTI) President Craig Philips to Present at Invest Northwest 2Health News:Medical costs for one premature baby could cover a dozen healthy births 2Health News:Medical costs for one premature baby could cover a dozen healthy births 3Health News:JumpStart and Case Technology Ventures Invest in Neuros Medical 2Health News:JumpStart and Case Technology Ventures Invest in Neuros Medical 3Health News:JumpStart and Case Technology Ventures Invest in Neuros Medical 4Health News:JumpStart and Case Technology Ventures Invest in Neuros Medical 5
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: